State of oncological care in Russia: bladder cancer (С67). Incidence, quality of patient followup, annual mortality. Part I

Background. Bladder cancer (С67) remains a serious problem of modern medicine without an established system of active detection. Among male population, bladder cancer is close to such malignant neoplasms as kidney cancer and systemic neoplasms of the lymphatic and hematopoietic tissues, while among female population to oral and brain neoplasms. In terms of 5-year cumulative, observed and relative survival bladder cancer is similar to malignant tumors of the parotid gland (С07) and leukemias (С91–96). Bladder cancer has a higher tendency to recurrence and progression.

Aim. To study for the first time on population level current dynamics of morbidity, mortality, accuracy of registering of patients with bladder cancer in Russia and to evaluate specifics of annual mortality of the patients based on the Population Cancer Registry (PCR) database of the Northwestern Federal District of the Russian Federation (NWFD RF).

Materials and methods. Materials of the International Agency for the Research on Cancer, P.A. Herzen Moscow Oncology Research Institute and N.N. Petrov National Medical Research Center of Oncology reference books were used. Detailed characteristics of the analytical values were established based on the NWFD RF PCR database. For calculation of annual bladder cancer mortality, 27,431 observations were selected from the PCR database.

Results and conclusion. The study allowed to determine the specifics of bladder cancer morbidity in the world, Russia, and NWFD RF, establish age characteristics of the registered bladder cancer cases. Dynamics of bladder cancer morbidity and mortality in Russia and NWFD RF were demonstrated. The negative effect of COVID-19 pandemic was observed. Positive dynamics in mortality and quality of follow-up for patients with bladder cancer were shown. Based in the PCR NWFD RF database, specifics of annual mortality of patients with bladder cancer were determined.

1. Sung H., Ferlay J., Siegel R. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660

2. Halaseh S.A., Halaseh S., Alali Y. et al. A review of the etiology and epidemiology of bladder cancer: all you need to know. Cureus 2022;14(7):e27330. DOI: 10.7759/cureus.27330

3. Edwards T.J., Dickinson A.J., Natale S. et al. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int 2006;97(2):301–5; discussion 305.

4. Fradet Y. Screening for bladder cancer: the best opportunity to reduce mortality. Can Urol Assoc J 2009;3(6 Suppl 4):S180–3. DOI: 10.5489/cuaj.1192

5. Jubber I., Ong S., Bukavina L. et al. Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol 2023;84(2):176–90. DOI: 10.1016/j.eururo.2023.03.029

6. Van Hoogstraten L.M.C., Vrieling A., van der Heijden A.G. et al. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol 2023;20(5):287–304. DOI: 10.1038/s41571-023-00744-3

7. Bray F., Colombet M., Aitken J.F. et al. Cancer Incidence in Five Continents. Vol. XII. International Agency for Research on Cancer. Lyon, 2023. Available at: https://ci5.iarc.who.int

8. Malignant tumors in Russia in 2015 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2017. 250 p. (In Russ.).

9. State of oncological care in Russia in 2023. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 262 p. (In Russ.).

10. Antoni S., Ferlay J., Soerjomataram I. et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017;71(1):96–108. DOI: 10.1016/j.eururo.2016.06.010

11. Teoh J.Y., Huang J., Ko W.Y. et al. Global Trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur Urol 2020;78(6):893– 906. DOI: 10.1016/j.eururo.2020.09.006

12. Freedman N.D., Silverman D.T., Hollenbeck A.R. et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306(7):737–45. DOI: 10.1001/jama.2011.1142

13. Zhang Y., Rumgay H., Li M. et al. The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040. J Global Health 2023;13. Available at: https://www.ncbi.nlm.nih. gov/pmc/articles/PMC10502766/ (date accessed: 15.10.2024).

14. Zhuikova L.D., Ananina O.A., Pikalova L.V., Kononova G.A. The impact of the COVID-19 pandemic on cancer incidence and cancer care in patients with prostate cancer in the Siberian Federal District. Onkourologiya = Cancer Urology 2022;18(3):135–44. (In Russ.). DOI: 10.17650/1726-9776-2022-18-3-135-144

15. Yurkova Yu.P., Merabishvili V.M., Tsvetkova (Chereyskaya) T.L. Malignant neoplasms and SARS-CoV-2 coronavirus. Retrospective analysis. Voprosy onkologii = Problems in Oncology 2023;69(3S):428–30. (In Russ.).

16. Malignant tumors in Russia in 2019 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2020. 252 p. (In Russ.).

17. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).

18. State of oncological care in Russia in 2021. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 239 p. (In Russ.).

19. Malignant tumors in Russia in 2010 (morbidity and mortality). Eds.: V.I. Chissov, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena Minzdravsotsrazvitiya Rossii, 2012. 260 p. (In Russ.).

20. Malignant tumors in Russia in 2000 (morbidity and mortality). Eds.: V.I. Chissov, V.V. Starinskiy. Moscow: MNIOI im. P.A. Gertsena Minzdravsotsrazvitiya Rossii, 2002. 264 p. (In Russ.).

21. Merabishvili V.M. Oncological statistics (traditional methods, new information technologies): Guidelines for doctors. 2nd edn., revised. Part I. Saint Petersburg: IPK “KOSTA”, 2015. 223 p. (In Russ.).

22. Merabishvili V.M. Malignant neoplasms in Northwestern Federal District of Russia (morbidity, mortality, follow-up accuracy, patient survival). Express-informatsia. Issue 5. Eds.: A.M. Belyaev, A.M. Scherbakov. Saint Petersburg: Izdatelskie tekhnologii, 2020. 236 p. (In Russ.).

23. Merabishvili V.M. Oncological statistics (traditional methods, new information technologies): Guidelines for doctors. 2nd edn., revised. Part II. Saint Petersburg: IPK “KOSTA”, 2015. (In Russ.).

24. Merabishvili V.M. Malignant neoplasms in Northwestern Federal District of Russia (morbidity, mortality, follow-up accuracy, patient survival). Express information. Issue 6. Eds.: A.M. Belyaev. Saint Petersburg: Izdatelskie tekhnologii, 2023. 498 p. (In Russ.).

25. Al-Zalabani A., Stewart K., Wesselius A. et al. Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses. Eur J Epidemiol 2016;31(9):811–51. DOI: 10.1007/s10654-016-0138-6

26. Kurahashi N., Inoue M., Liu Y. et al. Passive smoking and lung cancer in Japanese non-smoking women: a prospective study. Int J Cancer 2008;122(3):653–7. DOI: 10.1002/ijc.23116

27. Keimling M., Behrens G., Schmid D. et al. The association between physical activity and bladder cancer: systematic review and meta-analysis. Br J Cancer 2014;110(7):1862–70. DOI: 10.1038/bjc.2014.77

28. D’Andrea D., Black P.C., Zargar H. et al. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol 2020;38(7):639.e1–9. DOI: 10.1016/j.urolonc.2020.01.010

29. Stangl F.P., Buehler O.D., Wuethrich P.Y. et al. Sex does not affect survival: a propensity score-matched comparison in a homogenous contemporary radical cystectomy cohort. Clin Genitourin Cancer 2024;22(2):171–80. DOI: 10.1016/j.clgc.2023.10.009

30. Atduev V.A., Kushaev Z.K., Ledyaev D.S. et al. Long-term results of radical cystectomy in women with bladder cancer. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2020;9(6):12–7. (In Russ.). DOI: 10.17116/onkolog2020906112

31. Dobruch J., Daneshmand S., Fisch M. et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 2016;69(2):300–10. DOI: 10.1016/j.eururo.2015.08.037

32. Buteau A., Seideman C.A., Svatek R.S. et al. What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. Urol Oncol 2014;32(2):128–34. DOI: 10.1016/j.urolonc.2012.07.001

33. Hollenbeck B.K., Dunn R.L., Ye Z. et al. Delays in diagnosis and bladder cancer mortality. Cancer 2010;116(22):5235–42. DOI: 10.1002/cncr.25310

34. Noel O.D., Stewart E., Cress R. et al. Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006–2018: effect of race, age and socioeconomic status on treatment disparities. Urol Oncol 2023;41(10):431.e7–14. DOI: 10.1016/j.urolonc.2023.05.019

35. Lin W., Pan X., Zhang C. et al. Impact of age at diagnosis of bladder cancer on survival: a surveillance, epidemiology, and end results-based study 2004–2015. Cancer Control 2023;30:10732748231152322. DOI: 10.1177/10732748231152322

36. Duwe G., Wagner I., Banasiewicz K.E. et al. Radical cystectomy in patients aged < 80 years versus ≥ 80 years: analysis of preoperative geriatric assessment scores in predicting postoperative morbidity and mortality. World J Urol 2024;42(1):552. DOI: 10.1007/s00345-024-05248-y

37. Koppie T.M., Serio A.M., Vickers A.J. et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008;112(11):2384–92. DOI: 10.1002/cncr.23462

38. Williams S.B., Kamat A.M., Chamie K. et al. Systematic review of comorbidity and competing-risks assessments for bladder cancer patients. Eur Urol Oncol 2018;1(2):91–100. DOI: 10.1016/j.euo.2018.03.005

39. Berkut M.V., Nosov A.K. Ten-year experience of radical cystectomy in one center: retrospective analysis and oncological results. Onkourologiya = Cancer Urology 2024;20(4):60–74. (In Russ.). DOI: https://doi.org/10.17650/1726-9776-2024-20-4-60-74

40. Froehner M., Brausi M.A., Herr H.W. et al. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol 2009;56(3):443–54. DOI: 10.1016/j.eururo.2009.05.008